Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells.

Vernon PJ, Loux TJ, Schapiro NE, Kang R, Muthuswamy R, Kalinski P, Tang D, Lotze MT, Zeh HJ 3rd.

J Immunol. 2013 Feb 1;190(3):1372-9. doi: 10.4049/jimmunol.1201151. Epub 2012 Dec 26.

2.

The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia.

Kang R, Loux T, Tang D, Schapiro NE, Vernon P, Livesey KM, Krasinskas A, Lotze MT, Zeh HJ 3rd.

Proc Natl Acad Sci U S A. 2012 May 1;109(18):7031-6. doi: 10.1073/pnas.1113865109. Epub 2012 Apr 16.

3.

Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.

Zhang Y, Velez-Delgado A, Mathew E, Li D, Mendez FM, Flannagan K, Rhim AD, Simeone DM, Beatty GL, Pasca di Magliano M.

Gut. 2017 Jan;66(1):124-136. doi: 10.1136/gutjnl-2016-312078. Epub 2016 Jul 8.

4.

Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.

Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, Greenberg PD, Hingorani SR.

Gut. 2014 Nov;63(11):1769-81. doi: 10.1136/gutjnl-2013-306271. Epub 2014 Feb 20.

5.

The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression.

Seifert L, Werba G, Tiwari S, Giao Ly NN, Alothman S, Alqunaibit D, Avanzi A, Barilla R, Daley D, Greco SH, Torres-Hernandez A, Pergamo M, Ochi A, Zambirinis CP, Pansari M, Rendon M, Tippens D, Hundeyin M, Mani VR, Hajdu C, Engle D, Miller G.

Nature. 2016 Apr 14;532(7598):245-9. doi: 10.1038/nature17403. Epub 2016 Apr 6.

6.

Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer.

Song J, Lee J, Kim J, Jo S, Kim YJ, Baek JE, Kwon ES, Lee KP, Yang S, Kwon KS, Kim DU, Kang TH, Park YY, Chang S, Cho HJ, Kim SC, Koh SS, Kim S.

Oncotarget. 2016 Aug 9;7(32):51840-51853. doi: 10.18632/oncotarget.10123.

7.

Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH.

Cancer Cell. 2012 Jun 12;21(6):822-35. doi: 10.1016/j.ccr.2012.04.025.

8.

T-cell programming in pancreatic adenocarcinoma: a review.

Seo YD, Pillarisetty VG.

Cancer Gene Ther. 2017 Mar;24(3):106-113. doi: 10.1038/cgt.2016.66. Epub 2016 Dec 2. Review.

PMID:
27910859
9.

Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor.

Connolly MK, Mallen-St Clair J, Bedrosian AS, Malhotra A, Vera V, Ibrahim J, Henning J, Pachter HL, Bar-Sagi D, Frey AB, Miller G.

J Leukoc Biol. 2010 Apr;87(4):713-25. doi: 10.1189/jlb.0909607. Epub 2009 Dec 30.

10.

Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.

Hermann PC, Sancho P, Cañamero M, Martinelli P, Madriles F, Michl P, Gress T, de Pascual R, Gandia L, Guerra C, Barbacid M, Wagner M, Vieira CR, Aicher A, Real FX, Sainz B Jr, Heeschen C.

Gastroenterology. 2014 Nov;147(5):1119-33.e4. doi: 10.1053/j.gastro.2014.08.002. Epub 2014 Aug 12.

PMID:
25127677
11.

RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer.

DiNorcia J, Lee MK, Moroziewicz DN, Winner M, Suman P, Bao F, Remotti HE, Zou YS, Yan SF, Qiu W, Su GH, Schmidt AM, Allendorf JD.

J Gastrointest Surg. 2012 Jan;16(1):104-12; discussion 112. doi: 10.1007/s11605-011-1754-9. Epub 2011 Nov 4.

12.

The immune network in pancreatic cancer development and progression.

Wörmann SM, Diakopoulos KN, Lesina M, Algül H.

Oncogene. 2014 Jun 5;33(23):2956-67. doi: 10.1038/onc.2013.257. Epub 2013 Jul 15. Review.

PMID:
23851493
13.

CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer.

Karakasheva TA, Waldron TJ, Eruslanov E, Kim SB, Lee JS, O'Brien S, Hicks PD, Basu D, Singhal S, Malavasi F, Rustgi AK.

Cancer Res. 2015 Oct 1;75(19):4074-85. doi: 10.1158/0008-5472.CAN-14-3639. Epub 2015 Aug 20.

14.

Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance.

Daley D, Mani VR, Mohan N, Akkad N, Ochi A, Heindel DW, Lee KB, Zambirinis CP, Pandian GSB, Savadkar S, Torres-Hernandez A, Nayak S, Wang D, Hundeyin M, Diskin B, Aykut B, Werba G, Barilla RM, Rodriguez R, Chang S, Gardner L, Mahal LK, Ueberheide B, Miller G.

Nat Med. 2017 May;23(5):556-567. doi: 10.1038/nm.4314. Epub 2017 Apr 10.

15.

A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.

Yamaguchi T, Ikehara S, Nakanishi H, Ikehara Y.

J Pathol. 2014 Oct;234(2):228-38. doi: 10.1002/path.4402. Epub 2014 Aug 4.

PMID:
25042889
16.

Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.

Hosoi A, Matsushita H, Shimizu K, Fujii S, Ueha S, Abe J, Kurachi M, Maekawa R, Matsushima K, Kakimi K.

Int J Cancer. 2014 Apr 15;134(8):1810-22. doi: 10.1002/ijc.28506. Epub 2013 Oct 21.

17.

Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma.

Murakami S, Shahbazian D, Surana R, Zhang W, Chen H, Graham GT, White SM, Weiner LM, Yi C.

Oncogene. 2017 Mar 2;36(9):1232-1244. doi: 10.1038/onc.2016.288. Epub 2016 Aug 22.

18.
19.

Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.

Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, Rizzuto GA, Lazarus JJ, Pamer EG, Houghton AN, Merghoub T, Wolchok JD.

Cancer Res. 2012 Feb 15;72(4):876-86. doi: 10.1158/0008-5472.CAN-11-1792. Epub 2011 Dec 15.

20.

CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis.

Hiraoka N, Yamazaki-Itoh R, Ino Y, Mizuguchi Y, Yamada T, Hirohashi S, Kanai Y.

Gastroenterology. 2011 Jan;140(1):310-21. doi: 10.1053/j.gastro.2010.10.009. Epub 2010 Oct 16.

PMID:
20955708

Supplemental Content

Support Center